Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Epirus Biopharmaceuticals Inc    EPRSQ

 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
0(c) 0.0177(c) 0(c) 0.015(c) 0.015(c) Last
171 3 334 116 51 659 6 563 Volume
-100.00% -100.00% 0.00% Change
More quotes
Company
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business.It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on EPIRUS BIOPHARMACEUTICALS
2016 EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars ..
2016 EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financi..
2016 EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Fina..
2016 EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for..
2016 EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare..
2016DJJ&J, AbbVie Shares Drop on Potential Drug Competition
2016 EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global He..
2015 EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Inflixi..
2015 EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Prov..
2015 EPIRUS Biopharmaceuticals Reschedules Its Third Quarter 2015 Financial Result..
More news
Sector news : Biotechnology & Medical Research - NEC
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Biotechnology & Medical Research - NEC
Chart EPIRUS BIOPHARMACEUTICALS
Duration : Period :
Epirus Biopharmaceuticals  Technical Analysis Chart | EPRSQ | US29428P1075 | 4-Traders
Income Statement Evolution
Sector and Competitors
1st jan.Capitalization (M$)
EPIRUS BIOPHARMACEUTICALS INC-47.37%0
INCYTE CORPORATION14.00%24 079
QUINTILES IMS HOLDINGS INC31.30%21 478
LONZA GROUP64.29%20 495
CELLTRION, INC.--.--%18 458
ALNYLAM PHARMACEUTICALS, INC.228.53%11 283